Lineage Cell Therapeutics, Inc. (LCTX) Operating cash flow 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$18.9MFY2025 · since FY2016: -$42.3M → -$18.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$18.9M | +18.1% |
| FY2024 | -$23.1M | +19.2% |
| FY2023 | -$28.6M | -2797.5% |
| FY2022 | $1.1M | +104.5% |
| FY2021 | -$23.6M | -19.3% |
| FY2020 | -$19.8M | +38.2% |
| FY2019 | -$31.9M | -3.4% |
| FY2018 | -$30.9M | -1.2% |
| FY2017 | -$30.5M | +27.9% |
| FY2016 | -$42.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice